BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schwabl P, Mandorfer M, Steiner S, Scheiner B, Chromy D, Herac M, Bucsics T, Hayden H, Grabmeier-Pfistershammer K, Ferlitsch A, Oberhuber G, Trauner M, Peck-Radosavljevic M, Reiberger T. Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease. Aliment Pharmacol Ther. 2017;45:139-149. [PMID: 27910154 DOI: 10.1111/apt.13844] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 10.2] [Reference Citation Analysis]
Number Citing Articles
1 Khoo T, Lam D, Olynyk JK. Impact of modern antiviral therapy of chronic hepatitis B and C on clinical outcomes of liver disease. World J Gastroenterol 2021; 27(29): 4831-4845 [PMID: 34447229 DOI: 10.3748/wjg.v27.i29.4831] [Reference Citation Analysis]
2 Mandorfer M, Kozbial K, Schwabl P, Chromy D, Semmler G, Stättermayer AF, Pinter M, Hernández-Gea V, Fritzer-Szekeres M, Steindl-Munda P, Trauner M, Peck-Radosavljevic M, García-Pagán JC, Ferenci P, Reiberger T. Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy. Hepatology 2020;71:1023-36. [PMID: 31365764 DOI: 10.1002/hep.30885] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 15.7] [Reference Citation Analysis]
3 Mandorfer M, Reiberger T, Peck-Radosavljevic M. Monitoring the Evolution of Portal Hypertension After Sustained Virologic Response. Gastroenterology. 2018;154:1550-1551. [PMID: 29526728 DOI: 10.1053/j.gastro.2017.08.078] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
4 Semmler G, Scheiner B, Schwabl P, Bucsics T, Paternostro R, Chromy D, Stättermayer AF, Trauner M, Mandorfer M, Ferlitsch A, Reiberger T. The impact of hepatic steatosis on portal hypertension. PLoS One 2019;14:e0224506. [PMID: 31693695 DOI: 10.1371/journal.pone.0224506] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
5 Kreisel W, Lazaro A, Trebicka J, Grosse Perdekamp M, Schmitt-Graeff A, Deibert P. Cyclic GMP in Liver Cirrhosis-Role in Pathophysiology of Portal Hypertension and Therapeutic Implications. Int J Mol Sci 2021;22:10372. [PMID: 34638713 DOI: 10.3390/ijms221910372] [Reference Citation Analysis]
6 Mandorfer M, Simbrunner B. Prevention of First Decompensation in Advanced Chronic Liver Disease. Clin Liver Dis 2021;25:291-310. [PMID: 33838851 DOI: 10.1016/j.cld.2021.01.003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Mandorfer M, Turon F, Lens S, Baiges A, García-Criado Á, Darnell A, Belmonte E, Ferrusquía-Acosta J, Magaz M, Perez-Campuzano V, Olivas P, Bauer D, Casanovas G, Torres F, Mariño Z, Forns X, Hernández-Gea V, García-Pagán JC. Risk of non-tumoural portal vein thrombosis in patients with HCV-induced cirrhosis after sustained virological response. Liver Int 2021. [PMID: 34242479 DOI: 10.1111/liv.15009] [Reference Citation Analysis]
8 Isfordink CJ, Maan R, de Man RA, van Erpecum KJ, van der Meer AJ. Should we continue surveillance for hepatocellular carcinoma and gastroesophageal varices in patients with cirrhosis and cured HCV infection? Eur J Intern Med 2021:S0953-6205(21)00296-X. [PMID: 34563447 DOI: 10.1016/j.ejim.2021.08.023] [Reference Citation Analysis]
9 Olveira A, Domínguez L, Troya J, Arias A, Pulido F, Ryan P, Benítez LM, González-García J, Montes ML; PALT-M-Study Group Investigators. Persistently altered liver test results in hepatitis C patients after sustained virological response with direct-acting antivirals. J Viral Hepat 2018;25:818-24. [PMID: 29476581 DOI: 10.1111/jvh.12883] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
10 Artru F, Louvet A, Glowacki F, Bellati S, Frimat M, Gomis S, Castel H, Barthelon J, Lassailly G, Dharancy S, Noel C, Hazzan M, Mathurin P. The prognostic impact of cirrhosis on patients receiving maintenance haemodialysis. Aliment Pharmacol Ther 2019;50:75-83. [PMID: 31087566 DOI: 10.1111/apt.15279] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Medrano LM, Berenguer J, Salgüero S, González-García J, Díez C, Hontañón V, Garcia-Broncano P, Ibañez-Samaniego L, Bellón JM, Jiménez-Sousa MA, Resino S. Successful HCV Therapy Reduces Liver Disease Severity and Inflammation Biomarkers in HIV/HCV-Coinfected Patients With Advanced Cirrhosis: A Cohort Study. Front Med (Lausanne) 2021;8:615342. [PMID: 33598470 DOI: 10.3389/fmed.2021.615342] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Saracco GM, Marzano A, Rizzetto M. Therapy of Chronic Viral Hepatitis: The Light at the End of the Tunnel? Biomedicines 2022;10:534. [DOI: 10.3390/biomedicines10030534] [Reference Citation Analysis]
13 Laursen TL, Sandahl TD, Kazankov K, Eriksen PL, Kristensen LH, Holmboe CH, Laursen AL, Vilstrup H, Grønbæk H. Early normalization of reduced urea synthesis capacity after direct-acting antiviral therapy in hepatitis C cirrhosis. Am J Physiol Gastrointest Liver Physiol 2020;319:G151-6. [PMID: 32597708 DOI: 10.1152/ajpgi.00128.2020] [Reference Citation Analysis]
14 Semmler G, Binter T, Kozbial K, Schwabl P, Hametner-Schreil S, Zanetto A, Gavasso S, Chromy D, Bauer DJM, Simbrunner B, Scheiner B, Bucsics T, Stättermayer AF, Pinter M, Steindl-Munda P, Schöfl R, Russo FP, Simioni P, Trauner M, Ferenci P, Reiberger T, Mandorfer M. Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease. Hepatology 2021;73:1275-89. [PMID: 32659847 DOI: 10.1002/hep.31462] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
15 Li H. Angiogenesis in the progression from liver fibrosis to cirrhosis and hepatocelluar carcinoma. Expert Rev Gastroenterol Hepatol 2021;15:217-33. [PMID: 33131349 DOI: 10.1080/17474124.2021.1842732] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Bradley C, Scott RA, Cox E, Palaniyappan N, Thomson BJ, Ryder SD, Irving WL, Aithal GP, Guha IN, Francis S. Short-term changes observed in multiparametric liver MRI following therapy with direct-acting antivirals in chronic hepatitis C virus patients. Eur Radiol 2019;29:3100-7. [PMID: 30506214 DOI: 10.1007/s00330-018-5788-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
17 Mandorfer M, Hernández-gea V, Reiberger T, García-pagán JC. Hepatic Venous Pressure Gradient Response in Non-Selective Beta-Blocker Treatment—Is It Worth Measuring? Curr Hepatology Rep 2019;18:174-86. [DOI: 10.1007/s11901-019-00469-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
18 Bauer D, Kozbial K, Schwabl P, Chromy D, Simbrunner B, Stättermayer AF, Pinter M, Steindl-munda P, Trauner M, Ferenci P, Reiberger T, Mandorfer M. Angiopoietin 2 levels decrease after HCV-cure and reflect the evolution of portal hypertension. Digestive and Liver Disease 2022. [DOI: 10.1016/j.dld.2022.02.013] [Reference Citation Analysis]
19 Bulteel N, Leen C. Editorial: direct-acting anti-virals - not the be-all and end-all in HIV/HCV co-infection. Aliment Pharmacol Ther 2017;45:569-70. [PMID: 28074513 DOI: 10.1111/apt.13884] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
20 . UEG Week 2018 Poster Presentations. United European Gastroenterol j 2018;6. [DOI: 10.1177/2050640618792819] [Cited by in Crossref: 16] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
21 Mandorfer M, Scheiner B, Stättermayer AF, Schwabl P, Paternostro R, Bauer D, Schaefer B, Zoller H, Peck-Radosavljevic M, Trauner M, Reiberger T, Ferenci P, Ferlitsch A. Impact of patatin-like phospholipase domain containing 3 rs738409 G/G genotype on hepatic decompensation and mortality in patients with portal hypertension. Aliment Pharmacol Ther 2018;48:451-9. [PMID: 29956823 DOI: 10.1111/apt.14856] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
22 Simbrunner B, Mandorfer M, Trauner M, Reiberger T. Gut-liver axis signaling in portal hypertension. World J Gastroenterol 2019; 25(39): 5897-5917 [PMID: 31660028 DOI: 10.3748/wjg.v25.i39.5897] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 19] [Article Influence: 8.7] [Reference Citation Analysis]
23 Königshofer P, Brusilovskaya K, Schwabl P, Podesser BK, Trauner M, Reiberger T. Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats. J Vis Exp 2018. [PMID: 30124644 DOI: 10.3791/57261] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
24 Rossotti R, Garcia-fraile Fraile LJ, Baiguera C, Puoti M. Letter: sustained virological response and liver healing. Aliment Pharmacol Ther 2017;45:1171-3. [DOI: 10.1111/apt.13982] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
25 Mauro E, Crespo G, Montironi C, Londoño M, Hernández-gea V, Ruiz P, Sastre L, Lombardo J, Mariño Z, Díaz A, Colmenero J, Rimola A, Garcia-pagán JC, Brunet M, Forns X, Navasa M. Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C: Mauro et al. Hepatology 2018;67:1683-94. [DOI: 10.1002/hep.29557] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 16.5] [Reference Citation Analysis]
26 Scheiner B, Steininger L, Semmler G, Unger LW, Schwabl P, Bucsics T, Paternostro R, Ferlitsch A, Trauner M, Reiberger T, Mandorfer M. Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease. Liver Int 2019;39:127-35. [PMID: 30107095 DOI: 10.1111/liv.13943] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
27 Gentile I, Scotto R, Coppola C, Staiano L, Amoruso DC, De Simone T, Portunato F, De Pascalis S, Martini S, Macera M, Viceconte G, Tosone G, Buonomo AR, Borgia G, Coppola N. Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity—LINA cohort). Hepatol Int 2019;13:66-74. [DOI: 10.1007/s12072-018-9914-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
28 Lens S, Baiges A, Alvarado-tapias E, Llop E, Martinez J, Fortea JI, Ibáñez-samaniego L, Mariño Z, Rodríguez-tajes S, Gallego A, Bañares R, Puente Á, Albillos A, Calleja JL, Torras X, Hernández-gea V, Bosch J, Villanueva C, García-pagán JC, Forns X. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. Journal of Hepatology 2020;73:1415-24. [DOI: 10.1016/j.jhep.2020.05.050] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 13.0] [Reference Citation Analysis]
29 Reiberger T, Püspök A, Schoder M, Baumann-Durchschein F, Bucsics T, Datz C, Dolak W, Ferlitsch A, Finkenstedt A, Graziadei I, Hametner S, Karnel F, Krones E, Maieron A, Mandorfer M, Peck-Radosavljevic M, Rainer F, Schwabl P, Stadlbauer V, Stauber R, Tilg H, Trauner M, Zoller H, Schöfl R, Fickert P. Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III). Wien Klin Wochenschr 2017;129:135-58. [PMID: 29063233 DOI: 10.1007/s00508-017-1262-3] [Cited by in Crossref: 62] [Cited by in F6Publishing: 49] [Article Influence: 12.4] [Reference Citation Analysis]
30 Mihăilă RG. Liver stiffness in chronic hepatitis C virus infection. Rom J Intern Med 2019;57:85-98. [PMID: 30447147 DOI: 10.2478/rjim-2018-0034] [Reference Citation Analysis]
31 Cuesta-Sancho S, Márquez-Coello M, Illanes-Álvarez F, Márquez-Ruiz D, Arizcorreta A, Galán-Sánchez F, Montiel N, Rodriguez-Iglesias M, Girón-González JA. Hepatitis C: Problems to extinction and residual hepatic and extrahepatic lesions after sustained virological response. World J Hepatol 2022; 14(1): 62-79 [DOI: 10.4254/wjh.v14.i1.62] [Reference Citation Analysis]
32 Schwarzer R, Reiberger T, Mandorfer M, Kivaranovic D, Hametner S, Hametner S, Paternostro R, Scheiner B, Schneeweiss-Friedl J, Trauner M, Schoefl R, Maieron A. The von Willebrand Factor antigen to platelet ratio (VITRO) score predicts hepatic decompensation and mortality in cirrhosis. J Gastroenterol 2020;55:533-42. [PMID: 31832759 DOI: 10.1007/s00535-019-01656-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
33 Bucsics T, Grasl B, Ferlitsch A, Schwabl P, Mandorfer M, Zinober K, Stern R, Chromy D, Scheiner B, Sieghart W, Peck-Radosavljevic M, Trauner M, Reiberger T. Point Shear Wave Elastography for Non-invasive Assessment of Liver Fibrosis in Patients with Viral Hepatitis. Ultrasound Med Biol 2018;44:2578-86. [PMID: 30241728 DOI: 10.1016/j.ultrasmedbio.2018.07.031] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
34 Haider L, Mandorfer M, Güngören Z, Reiberger T, Bastati N, Hodge JC, Chromy D, Trauner M, Herold C, Peck-Radosavljevic M, Ba-Ssalamah A. Noninvasive Monitoring of Liver Disease Regression after Hepatitis C Eradication Using Gadoxetic Acid-Enhanced MRI. Contrast Media Mol Imaging 2018;2018:8489709. [PMID: 30116164 DOI: 10.1155/2018/8489709] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
35 Laursen TL, Villesen IF, Leeming DJ, Karsdal MA, Sølund C, Tarp B, Kristensen LH, Holmboe CH, Leutscher P, Laursen AL, Gudmann NS, Grønbaek H. Altered balance between collagen formation and degradation after successful direct-acting antiviral therapy of chronic hepatitis C. J Viral Hepat 2021;28:236-44. [PMID: 33058390 DOI: 10.1111/jvh.13416] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Semmler G, Binter T, Kozbial K, Schwabl P, Chromy D, Bauer D, Simbrunner B, Müllner-Bucsics T, Scheiner B, Stättermayer A, Pinter M, Steindl-Munda P, Trauner M, Ferenci P, Reiberger T, Mandorfer M. Influence of Genetic Variants on Disease Regression and Outcomes in HCV-Related Advanced Chronic Liver Disease after SVR. J Pers Med 2021;11:281. [PMID: 33917196 DOI: 10.3390/jpm11040281] [Reference Citation Analysis]
37 Thabut D, Bureau C, Layese R, Bourcier V, Hammouche M, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Goria O, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle-Bladou C, Dao T, Pilette C, Silvain C, Christidis C, Capron D, Bernard-Chabert B, Hillaire S, Di Martino V, Sutton A, Audureau E, Roudot-Thoraval F, Nahon P; ANRS CO12 CirVir group. Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy. Gastroenterology 2019;156:997-1009.e5. [PMID: 30768988 DOI: 10.1053/j.gastro.2018.11.053] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 16.7] [Reference Citation Analysis]
38 Schwabl P, Brusilovskaya K, Supper P, Bauer D, Königshofer P, Riedl F, Hayden H, Fuchs CD, Stift J, Oberhuber G, Aschauer S, Bonderman D, Gnad T, Pfeifer A, Uschner FE, Trebicka J, Rohr-Udilova N, Podesser BK, Peck-Radosavljevic M, Trauner M, Reiberger T. The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats. Sci Rep 2018;8:9372. [PMID: 29921982 DOI: 10.1038/s41598-018-27656-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
39 Pfisterer N, Schmidbauer C, Riedl F, Maieron A, Stadlbauer V, Hennlich B, Schwarzer R, Puespoek A, Bucsics T, Effenberger M, Bota S, Gschwantler M, Peck-Radosavljevic M, Mandorfer M, Madl C, Trauner M, Reiberger T. Perceptions on the management of varices and on the use of albumin in patients with cirrhosis among GI specialists in Austria. Wien Klin Wochenschr. 2021;133:421-431. [PMID: 33270161 DOI: 10.1007/s00508-020-01769-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
40 Brochado-Kith Ó, Martínez I, Berenguer J, González-García J, Salgüero S, Sepúlveda-Crespo D, Díez C, Hontañón V, Ibañez-Samaniego L, Pérez-Latorre L, Fernández-Rodríguez A, Ángeles Jiménez-Sousa M, Resino S. HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients. Front Immunol 2021;12:723196. [PMID: 34497613 DOI: 10.3389/fimmu.2021.723196] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Stift J, Semmler G, Walzel C, Mandorfer M, Schwarzer R, Schwabl P, Paternostro R, Scheiner B, Wöran K, Pinter M, Stättermayer AF, Trauner M, Peck-Radosavljevic M, Ferlitsch A, Reiberger T. Transjugular aspiration liver biopsy performed by hepatologists trained in HVPG measurements is safe and provides important diagnostic information. Dig Liver Dis 2019;51:1144-51. [PMID: 30862438 DOI: 10.1016/j.dld.2019.01.020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
42 Pietsch V, Deterding K, Attia D, Ringe KI, Heidrich B, Cornberg M, Gebel M, Manns MP, Wedemeyer H, Potthoff A. Long-term changes in liver elasticity in hepatitis C virus-infected patients with sustained virologic response after treatment with direct-acting antivirals. United European Gastroenterol J 2018;6:1188-98. [PMID: 30288281 DOI: 10.1177/2050640618786067] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
43 Colecchia A, Ravaioli F, Marasco G, Festi D. Spleen Stiffness by Ultrasound Elastography. In: Berzigotti A, Bosch J, editors. Diagnostic Methods for Cirrhosis and Portal Hypertension. Cham: Springer International Publishing; 2018. pp. 113-37. [DOI: 10.1007/978-3-319-72628-1_8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
44 Laursen TL, Sandahl TD, Kazankov K, George J, Grønbæk H. Liver-related effects of chronic hepatitis C antiviral treatment. World J Gastroenterol 2020; 26(22): 2931-2947 [PMID: 32587440 DOI: 10.3748/wjg.v26.i22.2931] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
45 Ravaioli F, Montagnani M, Lisotti A, Festi D, Mazzella G, Azzaroli F. Noninvasive Assessment of Portal Hypertension in Advanced Chronic Liver Disease: An Update. Gastroenterol Res Pract 2018;2018:4202091. [PMID: 29977287 DOI: 10.1155/2018/4202091] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
46 Malin JJ, Boesecke C, Schwarze-Zander C, Wasmuth JC, Schlabe S, Trebicka J, Spengler U, Llibre JM, Jou T, Vasylyev M, Clotet B, Rockstroh JK. Liver stiffness regression after successful Hepatitis C treatment is independent of HIV coinfection. HIV Med 2019;20:230-6. [PMID: 30687989 DOI: 10.1111/hiv.12705] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
47 Attia D, Deterding K, Cornberg J, Gebel MJ, Cornberg M, Manns MP, Wedemeyer H, Potthoff A. Different kinetics of liver stiffness using shear wave elastography in patients with chronic hepatitis C infection treated with interferon-free regimens. European Journal of Gastroenterology & Hepatology 2019;31:67-74. [DOI: 10.1097/meg.0000000000001259] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
48 Unger LW, Mandorfer M, Reiberger T. Portal Hypertension after Liver Transplantation—Causes and Management. Curr Hepatology Rep 2019;18:59-66. [DOI: 10.1007/s11901-019-00450-8] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
49 Beer L, Mandorfer M, Bastati N, Poetter-Lang S, Tamandl D, Stoyanova DP, Elmer MC, Semmler G, Simbrunner B, Hodge JC, Sirlin CB, Reiberger T, Ba-Ssalamah A. Inter- and intra-reader agreement for gadoxetic acid-enhanced MRI parameter readings in patients with chronic liver diseases. Eur Radiol 2019;29:6600-10. [PMID: 31001679 DOI: 10.1007/s00330-019-06182-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
50 Corma-Gómez A, Macías J, Morano L, Rivero A, Téllez F, Ríos MJ, Santos M, Serrano M, Palacios R, Merino D, Real LM, De Los Santos I, Vera-Méndez FJ, Galindo MJ, Pineda JA; RIS-HEP13 and GEHEP 011 Study Groups. Liver Stiffness-Based Strategies Predict Absence of Variceal Bleeding in Cirrhotic Hepatitis C Virus-Infected Patients With and Without Human Immunodeficiency Virus Coinfection After Sustained Virological Response. Clin Infect Dis 2021;72:e96-e102. [PMID: 33211801 DOI: 10.1093/cid/ciaa1726] [Reference Citation Analysis]
51 Lens S, Berbel C, Forns X, García-pagán JC. Portal Hypertension Reverses Following Successful Antiviral Treatment for HCV: Fact or Fiction? Curr Hepatology Rep 2018;17:209-17. [DOI: 10.1007/s11901-018-0405-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
52 Ravaioli F, Conti F, Brillanti S, Andreone P, Mazzella G, Buonfiglioli F, Serio I, Verrucchi G, Bacchi Reggiani ML, Colli A, Marasco G, Colecchia A, Festi D. Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals. Dig Liver Dis. 2018;50:573-579. [PMID: 29567413 DOI: 10.1016/j.dld.2018.02.010] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 7.5] [Reference Citation Analysis]
53 Mandorfer M, Schwabl P, Peck-radosavljevic M, Reiberger T; the Vienna HIV & Liver Study Group and the Vienna Hepatic Hemodynamic Lab. Letter: sustained virological response and liver healing - authors' reply. Aliment Pharmacol Ther 2017;45:1173-4. [DOI: 10.1111/apt.13999] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
54 Mandorfer M, Hernández-Gea V, García-Pagán JC, Reiberger T. Noninvasive Diagnostics for Portal Hypertension: A Comprehensive Review. Semin Liver Dis 2020;40:240-55. [PMID: 32557480 DOI: 10.1055/s-0040-1708806] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
55 Moser S, Kozbial K, Laferl H, Schütz A, Reiberger T, Schwabl P, Gutic E, Schwanke C, Schubert R, Luhn J, Lang T, Schleicher M, Steindl-Munda P, Haltmayer H, Ferenci P, Gschwantler M. Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease. Eur J Gastroenterol Hepatol 2018;30:291-5. [PMID: 29120906 DOI: 10.1097/MEG.0000000000001027] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
56 Steiner S, Bucsics T, Schwabl P, Mandorfer M, Scheiner B, Aichelburg MC, Grabmeier-Pfistershammer K, Ferenci P, Trauner M, Peck-Radosavljevic M, Reiberger T. Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna. Wien Klin Wochenschr 2017;129:517-26. [PMID: 28130599 DOI: 10.1007/s00508-016-1162-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
57 Garbuzenko DV, Arefyev NO. Primary prevention of bleeding from esophageal varices in patients with liver cirrhosis: An update and review of the literature. J Evid Based Med 2020;13:313-24. [PMID: 33037792 DOI: 10.1111/jebm.12407] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Selicean S, Wang C, Guixé-Muntet S, Stefanescu H, Kawada N, Gracia-Sancho J. Regression of portal hypertension: underlying mechanisms and therapeutic strategies. Hepatol Int 2021;15:36-50. [PMID: 33544313 DOI: 10.1007/s12072-021-10135-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Schwabl P, Laleman W. Novel treatment options for portal hypertension. Gastroenterol Rep (Oxf). 2017;5:90-103. [PMID: 28533907 DOI: 10.1093/gastro/gox011] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
60 Jeyarajan AJ, Chung RT. Insights Into the Pathophysiology of Liver Disease in HCV/HIV: Does it End With HCV Cure? J Infect Dis 2020;222:S802-13. [PMID: 33245355 DOI: 10.1093/infdis/jiaa279] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]